Literature DB >> 3032937

Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells.

S T Sawyer, S B Krantz, E Goldwasser.   

Abstract

The binding of labeled erythropoietin (EP) to cell surface receptors and subsequent processing of the hormone within the cell was studied in erythroid cells procured from the spleens of mice infected with the anemia strain of Friend virus. These immature erythroid cells respond to EP in culture to differentiate into reticulocytes and erythrocytes. Radiolabeled EP (both iodinated and tritiated) binds to 800-1000 cell surface receptors on these cells at 4 degrees C. Using 125I-EP, we found that 300 of these cell surface receptors have a higher affinity for EP (Kd = 0.09 nM) than the remaining receptors (Kd = 0.57 nM). The number of molecules of EP bound per cell increased about 2-fold when binding was carried out at 37 degrees C. Treatment of the cell surface with pronase or removal of surface-bound EP with a low pH wash revealed that radiolabeled EP is internalized by the cells at 37 degrees C. Pulse chase experiments showed that degradation products of radiolabeled EP are released into the medium with a corresponding loss of label from the interior of the cell. Inhibitors of lysosomal function greatly reduced this degradation of 125I-EP. Since 180 of the 300 high affinity receptors and very few of the low affinity receptors are occupied at the concentration of EP which elicits the maximum biological response in these cells, we suggest that interaction of EP with the high affinity receptors are necessary for the full biological effect of the hormone. A different murine erythroleukemia cell line which does not differentiate in response to EP was found to have only the lower affinity binding sites for the hormone.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3032937

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.

Authors:  Sameer Doshi; Wojciech Krzyzanski; Susan Yue; Steven Elliott; Andrew Chow; Juan José Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

2.  Correction for non-ideal tracer pharmacokinetic disposition by disposition decomposition analysis (DDA).

Authors:  P Veng-Pedersen; S S Hong; J A Widness; R L Schmidt
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

Review 3.  Erythropoietin receptor. Subunit structure and activation.

Authors:  A D D'Andrea; L I Zon
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

4.  Structure and transcription of the mouse erythropoietin receptor gene.

Authors:  H Youssoufian; L I Zon; S H Orkin; A D D'Andrea; H F Lodish
Journal:  Mol Cell Biol       Date:  1990-07       Impact factor: 4.272

Review 5.  Erythropoietin: emerging role of erythropoietin in neonatal neuroprotection.

Authors:  Vijayeta Rangarajan; Sandra E Juul
Journal:  Pediatr Neurol       Date:  2014-06-24       Impact factor: 3.372

6.  Purification of human erythroid colony-forming units and demonstration of specific binding of erythropoietin.

Authors:  K Sawada; S B Krantz; J S Kans; E N Dessypris; S Sawyer; A D Glick; C I Civin
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

7.  In vitro-derived leukemic erythroid cell lines induced by a raf- and myc-containing retrovirus differentiate in response to erythropoietin.

Authors:  S P Klinken; N A Nicola; G R Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

8.  Erythropoietin receptors in polycythemia vera.

Authors:  R T Means; S B Krantz; S T Sawyer; H S Gilbert
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

9.  Pharmacodynamically optimized erythropoietin treatment combined with phlebotomy reduction predicted to eliminate blood transfusions in selected preterm infants.

Authors:  Matthew R Rosebraugh; John A Widness; Demet Nalbant; Gretchen Cress; Peter Veng-Pedersen
Journal:  Pediatr Res       Date:  2013-11-11       Impact factor: 3.756

10.  The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains.

Authors:  A D D'Andrea; A Yoshimura; H Youssoufian; L I Zon; J W Koo; H F Lodish
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.